Top Political Trading

Track stock trades of top politicians based on performance

Next Rebalance: 2026-07-01
Loading chart...
Portfolio Metrics
Total Return
--
Sharpe Ratio
--
Max Drawdown
--
Risk Level
--
Current Holdings
Loading holdings...
Rebalance History

Apr 1, 2026

6 4 4
AAPL, AMZN, AVGO +11 more

New Positions

ICHR 0.0% 25.0%
Recent news indicates a strong near-term outlook for Ichor. A significant Stifel upgrade to Buy with a price target impl... Recent news indicates a strong near-term outlook for Ichor. A significant Stifel upgrade to Buy with a price target implying ~29% upside highlights accelerating cyclical strength and renewed confidence in margin recovery. [๐Ÿ”—](https://cognitmarket.com/article/e794e62c/stifel-upgrades-ichor-holdings-stock-rating-on) This is supported by a Q4 2025 earnings beat and strong Q1 2026 revenue guidance ($250M vs. prior $240M+). [๐Ÿ”—](https://cognitmarket.com/article/e794e62c/stifel-upgrades-ichor-holdings-stock-rating-on) The new CEO's operational restructuring appears to be gaining traction, driving upward earnings revisions. While the stock has run up significantly, this new information suggests continued momentum driven by fundamental improvements in the coming quarter.
HL 0.0% 23.7%
Hecla's near-term outlook is supported by operational catalysts. The Lucky Friday surface cooling project is expected to... Hecla's near-term outlook is supported by operational catalysts. The Lucky Friday surface cooling project is expected to complete in H1 2026, enabling access to higher-grade ore. [๐Ÿ”—](https://cognitmarket.com/article/d05f1678/can-hecla-mining-hold-on-to-its-strong-silver) Additionally, the Keno Hill mine continues its production ramp-up. [๐Ÿ”—](https://cognitmarket.com/article/d05f1678/can-hecla-mining-hold-on-to-its-strong-silver) A potential tailings reprocessing project at Greens Creek presents long-term upside, with pilot plant results pending. [๐Ÿ”—](https://cognitmarket.com/article/cfe0fcce/envirogold-global-announces-positive-results-from) These operational positives are balanced by the stock's sensitivity to volatile precious metal prices, which are currently influenced by geopolitical events and macroeconomic factors like interest rates and dollar strength. [๐Ÿ”—](https://cognitmarket.com/article/08a3366f/us-mining-stocks-volatile-as-trump-delays-iran)
SCHW 0.0% 5.0%
Schwab's outlook is positive, driven by strong February metrics and upgraded guidance. The company reported accelerating... Schwab's outlook is positive, driven by strong February metrics and upgraded guidance. The company reported accelerating Q1 revenue growth of ~16% YoY and robust adjusted net new assets of $50 billion. [๐Ÿ”—](https://cognitmarket.com/article/5193fcc2/schwab-reports-32-5-billion-net-new-assets-in) The completed acquisition of Forge Global provides a new growth vector in private markets. [๐Ÿ”—](https://cognitmarket.com/article/cf5943aa/charles-schwab-completes-acquisition-of-forge) While analyst ratings are favorable, concerns about AI disruption and a recent insider sale introduce some caution. [๐Ÿ”—](https://cognitmarket.com/article/2a9037ae/howard-dennis-sells-956k-in-schwab-schw-stock) The upcoming May 14 investor day is a key near-term catalyst for strategic updates and financial targets. [๐Ÿ”—](https://cognitmarket.com/article/b4127394/charles-schwab-schedules-investor-day-for-may-14)
VST 0.0% 5.0%
Vistra's recent investment-grade rating upgrade from Fitch is a significant de-risking catalyst, improving its financial... Vistra's recent investment-grade rating upgrade from Fitch is a significant de-risking catalyst, improving its financial flexibility and lowering future borrowing costs. [๐Ÿ”—](https://cognitmarket.com/article/51708748/vistra-achieves-investment-grade-credit-ratings-s) This complements the strong, ongoing narrative of benefiting from AI-driven data center demand, evidenced by long-term power purchase agreements with major tech firms. [๐Ÿ”—](https://cognitmarket.com/article/1e199cfa/morgan-stanley-is-bullish-on-vistra-corp-vst-heres) While Q4 earnings missed estimates, strong 2026 guidance was reiterated, projecting significant EBITDA growth. [๐Ÿ”—](https://cognitmarket.com/article/461f72de/2-monster-energy-stocks-to-hold-for-the-next-10) This positive fundamental outlook, combined with the credit upgrade, suggests potential for near-term outperformance despite recent stock price weakness.

Increased Positions

AAPL 2.8% 5.0%
Positive near-term signals are driven by strong initial demand for new budget-focused products like the iPhone 17e and M... Positive near-term signals are driven by strong initial demand for new budget-focused products like the iPhone 17e and MacBook Neo, indicated by extended delivery times and favorable analyst commentary. [๐Ÿ”—](https://cognitmarket.com/article/5cd6638a/apple-neo-wait-time) These products could expand Apple's user base and drive ecosystem growth. Additionally, strong China sales (+23%) early in the year bucked market trends, suggesting resilient demand. [๐Ÿ”—](https://cognitmarket.com/article/0210408f/apples-china-smartphone-sales-jump-23-to-start) The upcoming WWDC in June is a key catalyst, with a focus on AI expected to address a perceived weakness. [๐Ÿ”—](https://cognitmarket.com/article/9e97f923/apple-schedules-wwdc-for-june-8-12-with-ai-focus) Risks include macro pressures and normalizing China shipments post-launch. [๐Ÿ”—](https://cognitmarket.com/article/df3944dd/apple-tesla-and-alphabet-all-sinking-as-oil-prices)
LLY 2.9% 5.0%
Eli Lilly's near-term outlook is positive, driven by strong GLP-1 momentum and pipeline advancements. The upcoming US la... Eli Lilly's near-term outlook is positive, driven by strong GLP-1 momentum and pipeline advancements. The upcoming US launch of oral orforglipron in Q2 2026 is a major catalyst, potentially expanding the market and defending its ~60% share against Novo Nordisk's new oral Wegovy. [๐Ÿ”—](https://cognitmarket.com/article/76ed51bc/will-policy-shifts-accelerate-demand-for-eli-lilly) Positive trial data for Taltz+Zepbound and retatrutide, plus strategic acquisitions in neuroscience (Centessa) and AI (Insilico), reinforce innovation beyond GLP-1s. [๐Ÿ”—](https://cognitmarket.com/article/dae37e61/eli-lilly-reaches-2-75-billion-deal-with-insilico) While one analyst cites pricing pressure risks, this is offset by expanding Medicare access and employer programs. [๐Ÿ”—](https://cognitmarket.com/article/0a34e88b/why-one-analyst-thinks-lly-is-worth-850-while-the)
AMZN 4.2% 5.0%
Strong, accelerating AWS growth (24% in Q4) driven by AI demand is a primary positive catalyst. This is reinforced by a... Strong, accelerating AWS growth (24% in Q4) driven by AI demand is a primary positive catalyst. This is reinforced by a newly confirmed, massive 1 million GPU deal with Nvidia starting this year, signaling sustained AI infrastructure investment and future capacity. [๐Ÿ”—](https://cognitmarket.com/article/de4587fc/alphabet-vs-amazon-both-ai-stocks-have-been-but-a) While rising fuel costs present a near-term operating income headwind of ~$880M for Q2, this is a known variable and likely partially priced in. [๐Ÿ”—](https://cognitmarket.com/article/32bbe874/wells-fargo-reiterates-amazon-stock-overweight-on) Continued retail efficiencies, such as faster delivery options, and a resilient ad business provide additional support, outweighing the fuel cost risk. [๐Ÿ”—](https://cognitmarket.com/article/e4602d55/bofa-reiterates-buy-on-amazon-stock-275-target-on)

Closed Positions

GOOGL 22.3% 0.0%
TSLA 11.8% 0.0%
The primary near-term catalyst is the Q1 delivery report on April 2nd, with consensus forecasting a significant sequenti... The primary near-term catalyst is the Q1 delivery report on April 2nd, with consensus forecasting a significant sequential decline to ~365k units. [๐Ÿ”—](https://cognitmarket.com/article/12db36a2/why-is-tesla-stock-rallying-today) Multiple analysts project a third consecutive year of delivery declines, citing weak demand, competition, and loss of subsidies. [๐Ÿ”—](https://cognitmarket.com/article/0781f1f3/tesla-delivery-slide-may-stretch-to-third-year-as) This core auto weakness is compounded by intensified federal probes into FSD and rising safety concerns, which undermine the AI/robotaxi narrative that supports the stock's high valuation. [๐Ÿ”—](https://cognitmarket.com/article/f6a3c734/glj-research-cuts-tesla-stock-rating-on-robotaxi) While long-term AI initiatives exist, near-term fundamentals are deteriorating, creating a negative risk/reward skew.
BAX 2.8% 0.0%
Baxter faces near-term headwinds. New governance and product safety investigations related to the Novum LVP product and... Baxter faces near-term headwinds. New governance and product safety investigations related to the Novum LVP product and alleged supply chain disclosure issues create uncertainty [๐Ÿ”—](https://cognitmarket.com/article/f7f222a3/the-bull-case-for-baxter-international-bax-could). The departure of the CFO adds to the instability [๐Ÿ”—](https://cognitmarket.com/article/55a67be3/baxter-names-interim-cfo-as-joel-grade-departs-for). Recent performance data shows a significant stock decline [๐Ÿ”—](https://cognitmarket.com/article/b92a3b1e/how-is-baxter-s-stock-performance-compared-to). While the IV Verify system launch is positive [๐Ÿ”—](https://cognitmarket.com/article/0da64c30/baxter-launches-iv-verify-automated-labeling-for), it's unlikely to offset these negative factors in the next 3 months. Technical indicators are mostly bearish (SMA20, SMA50, EMA12) (See Technical Indicators).
ARCC 2.8% 0.0%
No ARCC-specific, near-term incremental information was provided. Coverage is largely promotional (Motley Fool) and focu... No ARCC-specific, near-term incremental information was provided. Coverage is largely promotional (Motley Fool) and focuses on dividend attractiveness already known to the market. Multiple articles reference Ares Management (ARES) S&P 500 inclusion, which is not ARCC and offers minimal read-through. There are no new earnings, guidance, credit quality, or portfolio updates tied to the next three months. Usual upcoming catalysts (dividend declaration/earnings) are routine. Given lack of concrete revisions or catalysts and low signal quality, the near-term performance outlook is neutral with low confidence.

Decreased Positions

NVDA 25.3% 14.2%
Recent news reveals significant near-term catalysts. The new Marvell partnership, including a $2B investment, expands NV... Recent news reveals significant near-term catalysts. The new Marvell partnership, including a $2B investment, expands NVIDIA's AI ecosystem and reinforces its dominance in custom silicon and networking. [๐Ÿ”—](https://cognitmarket.com/article/139be9d0/why-is-nvidia-corporation-stock-surging-today) Additionally, the confirmation of a 1 million GPU sale to AWS through 2027 provides tangible evidence of sustained hyperscaler demand. [๐Ÿ”—](https://cognitmarket.com/article/86d74c25/nvidia-confirms-1-million-gpu-sale-to-aws-through) These developments, coupled with CEO commentary on an "inference inflection," suggest continued strong execution. While the stock has seen recent weakness and faces antitrust questions, these positive, concrete business developments are likely to drive outperformance over the next three months. [๐Ÿ”—](https://cognitmarket.com/article/e29c1bb7/why-nvidia-has-the-important-stock-chart-in-the)
IBKR 17.8% 7.1%
Interactive Brokers demonstrates strong near-term momentum through strategic product expansion. The recent launch of cry... Interactive Brokers demonstrates strong near-term momentum through strategic product expansion. The recent launch of crypto trading in the large EEA market and the introduction of a crypto transfer feature are poised to attract new clients and assets. [๐Ÿ”—](https://cognitmarket.com/article/793803da/interactive-brokers-launches-crypto-trading-for) February's metrics confirm this growth, showing significant year-over-year increases in client accounts, equity, and DARTs. [๐Ÿ”—](https://cognitmarket.com/article/ba6e9825/interactive-brokers-group-reports-brokerage-and) While some Reddit posts highlight customer service issues, these are anecdotal and outweighed by positive fundamental trends and upward analyst estimate revisions, suggesting continued outperformance. [๐Ÿ”—](https://cognitmarket.com/article/cb7e4112/something-weird-is-happening-at-ibkr-my-rights-are)
AVGO 7.4% 5.0%
Broadcom's near-term outlook is strongly positive, driven by accelerating AI revenue and custom chip demand. The company... Broadcom's near-term outlook is strongly positive, driven by accelerating AI revenue and custom chip demand. The company reported a 106% YoY increase in AI sales and projects this momentum to continue, targeting $100B in AI chip sales by fiscal 2027. [๐Ÿ”—](https://cognitmarket.com/article/65ca6123/2-ai-chip-stocks-i-d-buy-before-their-next-reports) A new $970M defense contract provides incremental revenue visibility. [๐Ÿ”—](https://cognitmarket.com/article/9daaded7/us-semiconductors-bofa-ranks-top-subsectors-and-ai) While Cathie Wood's sale is noted, it's minor against overwhelming positive fundamental data, strong analyst support, and a $10B buyback program, suggesting significant upside potential over the next three months. [๐Ÿ”—](https://cognitmarket.com/article/1cfd5b3b/cathie-wood-goes-on-a-selling-spree-3-stocks-she)

Jan 2, 2026

8 2 2
AAPL, AMZN, ARCC +9 more

New Positions

IBKR 0.0% 17.8%
Limited incremental, near-term information. Yahoo coverage is generic. Reddit posts cite potential cost-basis errors and... Limited incremental, near-term information. Yahoo coverage is generic. Reddit posts cite potential cost-basis errors and UI confusion on options/recurring buysโ€”possible customer-experience and support-cost risks, but single-source and anecdotal. Another Reddit thread notes attractive IBKR margin/PAL rates, a mild positive for balances/NIM, also anecdotal. Prediction-market commentary is long-term. No concrete guidance changes or verified operational updates; earnings/monthly activity metrics remain the next catalysts. Overall near-neutral with slight downside tilt, low reliability.
LLY 0.0% 2.9%
Near-term setup is modestly positive. Reuters reports FDA leadership pushing to accelerate review of Lillyโ€™s oral GLPโ€‘1... Near-term setup is modestly positive. Reuters reports FDA leadership pushing to accelerate review of Lillyโ€™s oral GLPโ€‘1 (possible verdict by Mar 28 vs prior May 20), creating a defined 3โ€‘month catalyst. Legislative moves to restrict compounded GLPโ€‘1s (multiple sources) could shift demand back to branded Zepbound/Mounjaro near term. Positive Phase 3 retatrutide data supports pipeline momentum. Offsetting: Novo Nordisk already has FDAโ€‘approved GLPโ€‘1 pill and a pricing head start, and both NVO/LLY agreed to price cuts for Medicare access, pressuring margins. Alabama plant is longerโ€‘dated. Rumored M&A (Abivax) is unconfirmed. Overall: moderate upside with clear catalyst, medium confidence.

Increased Positions

NVDA 21.5% 25.3%
Incremental positives: U.S. lawmakers reportedly excluded the GAIN AI export-priority measure from the defense bill, red... Incremental positives: U.S. lawmakers reportedly excluded the GAIN AI export-priority measure from the defense bill, reducing near-term regulatory downside risk to NVDAโ€™s international (incl. China-adjacent) demand; Reuters also highlighted NVDA inference-server data showing ~10x gains on mixture-of-experts models, supporting continued inference momentum. Broadcomโ€™s AI-driven results are a read-through that hyperscaler AI spend remains resilient. Offsetting risks: renewed โ€œAI bubble/capex sustainabilityโ€ narrative after Oracleโ€™s revenue miss, and inference competition remains a key debate. The Groq $20B deal chatter is unverified/low-credibility, limiting confidence.
TSLA 8.7% 11.8%
Near-term skew is negative. Multiple credible signals point to weak Q4: Cox shows U.S. Nov sales -23% YoY, articles flag... Near-term skew is negative. Multiple credible signals point to weak Q4: Cox shows U.S. Nov sales -23% YoY, articles flag delivery softness from EV-credit pull-forward, and a Yahoo-cited L&F filing shows a 99% cut to Cybertruck cathode orders, implying curtailed production/demand. Morgan Stanley downgraded; valuation remains stretched, raising downside risk if deliveries/earnings disappoint this month. Potential offsetsโ€”Muskโ€™s plan to remove safety drivers in Austin and RDW approval targeted for Febโ€”are uncertain/regulatory and may not translate to revenue near term. Net: likely underperformance into delivery/EPS prints; autonomy headlines are a wild card.
BAX 2.2% 2.8%
AMZN 3.7% 4.2%
Near-term setup skews positive. Multiple credible sources (HSBC, TD Cowen) flag robust Black Friday/Cyber Monday and AWS... Near-term setup skews positive. Multiple credible sources (HSBC, TD Cowen) flag robust Black Friday/Cyber Monday and AWS reacceleration into Q4, supporting upside to Feb earnings. Graviton5 launch with marquee adopters could aid AWS margins/mix near term. Five-year Affirm renewal sustains checkout conversion. Reports of a potential OpenAI investment and India quick-commerce push add optionality, though not confirmed. Key risks: elevated SBC optics/dilution, AI capex/bubble concerns, and sector volatility. Overall, catalysts outweigh risks over 3 months, but some elements are opinion-driven or unconfirmed, tempering confidence.
ARCC 2.7% 2.8%
No ARCC-specific, near-term incremental information was provided. Coverage is largely promotional (Motley Fool) and focu... No ARCC-specific, near-term incremental information was provided. Coverage is largely promotional (Motley Fool) and focuses on dividend attractiveness already known to the market. Multiple articles reference Ares Management (ARES) S&P 500 inclusion, which is not ARCC and offers minimal read-through. There are no new earnings, guidance, credit quality, or portfolio updates tied to the next three months. Usual upcoming catalysts (dividend declaration/earnings) are routine. Given lack of concrete revisions or catalysts and low signal quality, the near-term performance outlook is neutral with low confidence.

Closed Positions

MSFT 6.7% 0.0%
Near-term setup is mixed. Incremental negatives: mounting capex above guidance ($34.9B vs ~$30B) pressuring FCF/margins;... Near-term setup is mixed. Incremental negatives: mounting capex above guidance ($34.9B vs ~$30B) pressuring FCF/margins; reports Amazon may invest $10B+ in OpenAI could dilute Microsoftโ€™s strategic edge; broader AI financing/bubble risk tone. Positives: DA Davidson notes sizable but diversified OpenAI-driven Azure revenue; Microsoft denied AI quota-cut report; Azure/AI demand remains strong into FY26. Key 3โ€‘month catalyst is lateโ€‘Jan earnings/guide on Azure growth, Copilot monetization, and capex trajectory. With bullish sell-side already embedded, risk/reward slightly positive but not decisive.
COST 2.4% 0.0%
Incremental: Reuters/StreetInsider reports COST beat FQ1 revenue/earnings with ex-gas comps +6.4% vs 5.8% est, indicatin... Incremental: Reuters/StreetInsider reports COST beat FQ1 revenue/earnings with ex-gas comps +6.4% vs 5.8% est, indicating solid holiday demandโ€”a nearโ€‘term positive. However, rich valuation (~44x forward per MF) and a MarketWatch-flagged contrarian downgrade temper upside, suggesting rangebound risk. Instacart pricing investigation introduces minor reputational/experience risk but is indirect to Costco. Upcoming 1โ€“3 month catalysts: monthly sales updates and Q2 (Mar) results; fee-hike speculation lacks timing. Net: modest positive skew, moderate reliability given one strong data point and otherwise opinion-heavy sources.

Decreased Positions

AVGO 21.1% 7.4%
New, credible data points: Broadcomโ€™s Q4 beat with AI revenue +74%, AI backlog ~$73B, and guidance that AI revenue will... New, credible data points: Broadcomโ€™s Q4 beat with AI revenue +74%, AI backlog ~$73B, and guidance that AI revenue will more than double in Q1โ€”plus OpenAI and Alphabet TPU winsโ€”support nearโ€‘term topline strength into lateโ€‘Feb earnings. However, management flagged lower future margins on AI system sales, a key incremental risk that hit sector sentiment. Added risks: crowding warnings (JPM quants), AI spend skepticism (Oracle financing wobble). Offsets: 10% dividend hike, hyperscaler custom silicon momentum (Citi: Google spend doubling in 2026). Net: modest positive skew but tempered by margin/positioning risks.
GOOGL 26.8% 22.3%
AAPL 4.1% 2.8%
Near-term setup skews modestly positive on signs of a China iPhone rebound: CAICT November data (via Reddit) shows forei... Near-term setup skews modestly positive on signs of a China iPhone rebound: CAICT November data (via Reddit) shows foreign shipments +128% YoY, with Apple cited as primary driverโ€”supporting potential upside to the Dec-quarter (FQ1) print and near-term guidance. Evercoreโ€™s target raise and AI roadmap (Siri 2.0) bolster narrative but fall outside 3 months; Appleโ€™s SHARP AI model is early-stage. Offsetting: Berkshireโ€™s 15% trim (known since Q3) could be a lingering overhang. Overall, a possible FQ1 beat/constructive guide, but limited multi-source confirmation tempers confidence.

Oct 1, 2025

10 0 0
AAPL, AMZN, ARCC +7 more

Increased Positions

AVGO 15.1% 21.5%
AMZN 2.1% 3.8%
BAX 1.6% 2.8%
COST 1.9% 2.8%
ARCC 1.9% 2.8%
GOOGL 21.3% 22.1%

Decreased Positions

AAPL 12.4% 4.1%
MSFT 9.6% 7.8%
TSLA 11.4% 9.7%
NVDA 22.8% 22.7%

Jul 1, 2025

9 1 1
AAPL, AMZN, ARCC +8 more

New Positions

COST 0.0% 2.6%

Increased Positions

TSLA 5.2% 9.2%
AAPL 9.5% 12.4%
MSFT 9.8% 11.2%
BAX 1.9% 2.6%
ARCC 2.1% 2.6%
AMZN 2.4% 2.6%

Closed Positions

LLY 3.1% 0.0%

Decreased Positions

NVDA 28.0% 23.1%
AVGO 18.1% 14.8%
GOOGL 19.8% 18.9%

Apr 1, 2025

8 2 2
AAPL, AMZN, ARCC +9 more

New Positions

GOOGL 0.0% 21.8%
LLY 0.0% 3.9%

Increased Positions

AVGO 10.0% 14.1%
NVDA 21.6% 24.8%

Closed Positions

COST 2.8% 0.0%
HL 2.8% 0.0%

Decreased Positions

AMZN 15.4% 2.6%
MSFT 18.5% 9.3%
AAPL 16.7% 12.6%
BAX 3.2% 2.6%
TSLA 6.2% 5.7%
ARCC 2.8% 2.6%

Jan 2, 2025

8 2 2
AAPL, AMZN, ARCC +9 more

New Positions

TSLA 0.0% 7.5%
BAX 0.0% 2.3%

Increased Positions

MSFT 15.0% 17.4%
HL 1.5% 2.3%
COST 1.9% 2.3%
ARCC 2.0% 2.3%
AVGO 11.5% 11.7%

Closed Positions

IBKR 2.5% 0.0%
JPM 2.2% 0.0%

Decreased Positions

AAPL 19.5% 15.7%
NVDA 26.4% 23.2%
AMZN 17.4% 15.1%

Oct 1, 2024

7 3 3
AAPL, AMZN, ARCC +10 more

New Positions

AVGO 0.0% 9.5%
HL 0.0% 2.1%
IBKR 0.0% 2.1%

Increased Positions

AMZN 14.9% 16.7%
NVDA 24.2% 25.5%

Closed Positions

V 3.6% 0.0%
PANW 2.0% 0.0%
SCHW 1.8% 0.0%

Decreased Positions

AAPL 24.6% 20.6%
MSFT 19.6% 17.1%
COST 3.5% 2.1%
JPM 3.4% 2.1%
ARCC 2.4% 2.1%

Jul 1, 2024

10 0 0
AAPL, AMZN, ARCC +7 more

Increased Positions

MSFT 18.9% 20.6%
AMZN 14.3% 15.4%
JPM 2.5% 3.2%
ARCC 1.7% 2.3%
SCHW 1.7% 2.0%

Decreased Positions

NVDA 28.8% 25.0%
COST 3.5% 3.3%
AAPL 23.0% 22.8%
V 3.5% 3.4%
PANW 2.0% 2.0%

Apr 1, 2024

7 3 0
AAPL, AMZN, ARCC +7 more

New Positions

V 0.0% 4.4%
COST 0.0% 3.5%
PANW 0.0% 2.0%

Increased Positions

AAPL 17.3% 21.5%
JPM 1.8% 2.9%
MSFT 20.3% 21.0%
SCHW 1.7% 2.0%
AMZN 15.4% 15.7%

Decreased Positions

NVDA 36.8% 25.0%
ARCC 6.7% 2.0%

Jan 2, 2024

6 1 0
AAPL, AMZN, ARCC +4 more

New Positions

SCHW 0.0% 2.0%

Increased Positions

AAPL 21.9% 24.1%
NVDA 24.2% 25.0%
AMZN 15.6% 16.3%

Decreased Positions

JPM 4.1% 2.0%
MSFT 24.5% 22.5%
ARCC 9.7% 8.2%

Oct 2, 2023

5 1 0
AAPL, AMZN, JPM +3 more

New Positions

ARCC 0.0% 10.0%

Increased Positions

AAPL 21.6% 22.7%

Decreased Positions

AMZN 19.4% 14.9%
JPM 7.6% 3.8%
NVDA 27.0% 25.0%
MSFT 24.4% 23.6%

Jul 3, 2023

1 4 0
AMZN, AAPL, JPM +2 more

New Positions

MSFT 0.0% 25.0%
NVDA 0.0% 25.0%
AAPL 0.0% 23.4%
JPM 0.0% 7.5%

Decreased Positions

AMZN 100.0% 19.1%

Apr 3, 2023

0 1 0
AMZN

New Positions

AMZN 0.0% 100.0%